🧬 New publication International experts share key recommendations on biomarker testing in advanced/metastatic HR+/HER2- #breastcancer, offering practical guidance to support precision oncology and treatment decision-making. 📖 Read here: buff.ly/qkAjgAi #Oncology #Biomarkers #PrecisionMedicine

🧬 New research in esophagogastric cancer highlights the prognostic value of type V collagen biomarkers. Serum C-terminal pro-peptide levels may help identify desmoplasia subtypes with clinical relevance. Read more 👇 buff.ly/ov287mf #Oncology #CancerResearch #Biomarkers #PrecisionMedicine

🚨 Call for Papers! Submit to our special collection on bladder-sparing strategies in urothelial carcinoma 🧪 Novel therapies & combinations 📈 Emerging clinical insights 👉 Learn more & submit: buff.ly/x5jNw3U #CallForPapers #Oncology #CancerResearch

🆕 Rare epithelial gastric cancers remain an underexplored clinical challenge. This review synthesizes current treatment strategies & emerging insights to guide practice and future research. 🔗 Read the article buff.ly/V8qSVm8 #Oncology #GastricCancer #CancerResearch #ClinicalInsights

🚨 Call for Papers! Submit to our special collection: Clinical Trials Driving Innovation in Oncology 🧬 Share your latest research in Therapeutic Advances in Medical Oncology 📩 Submit here: buff.ly/bioqZyF #CallForPapers #Oncology #ClinicalTrials #CancerResearch

🧬 What’s next for EBV-positive #gastriccancer? This review highlights key molecular mechanisms and evolving therapeutic strategies, offering a comprehensive look at opportunities for more targeted, personalized care. 📖 Read:https://buff.ly/AAZpU90 #EBV #PrecisionOncology #CancerResearch

🧬 How is genomics reshaping our understanding of #ovariancancer? This review highlights the growing role of precision medicine in improving diagnosis and treatment pathways - offering insights into the future of personalized oncology care.🔗 Dive in: buff.ly/iqYxZYe #PrecisionOncology #CancerResearch

📣 Call for Papers - Special Collection: TME in GI Cancers 🔬 Biomarkers & clinical impact 🧬 Translational & clinical studies welcome 🗓 Deadline: 15 Mar 2027 👉 buff.ly/dpUqDMk #CallForPapers #Oncology #GICancers #CancerResearch

🧬 How should we sequence antibody–drug conjugates in metastatic breast cancer? This review maps the current landscape and evolving strategies for optimizing ADC use in clinical practice. 🔗 Read now: buff.ly/9SJkVZ1 #BreastCancer #Oncology #ADCs #CancerResearch

🧠 How can we better prevent & manage cytokine release syndrome (CRS) in solid tumours? This review explores mechanism-based therapeutic strategies to improve patient outcomes in oncology. 📖 Read now: buff.ly/ZDar0oT #Oncology #CancerResearch #Immunotherapy #CRS #MedEd

🧬 Can tumor-agnostic strategies unlock new options for SMARCA4-deficient malignancies? This reivew explores emerging therapeutic approaches across cancer types. 🔗 Read now: buff.ly/uc7XNaA #Oncology #PrecisionMedicine #TumorAgnostic #CancerResearch

🧬 What role does the tumor microenvironment play in lung adenocarcinoma metastases? This review explores key alterations & biomarkers—and their impact on treatment response and prognosis. 🔗 Read now: buff.ly/AzpRbgj #LungCancer #Oncology #TumorMicroenvironment #Biomarkers

🧬 Neoadjuvant trastuzumab + pertuzumab + carboplatin-based therapy shows promising results in HER2+ breast cancer—paired with integrated genomic & transcriptomic biomarker analysis. 🔗 Read now: buff.ly/WZ97gu5 #BreastCancer #HER2 #Oncology #Biomarkers

📊 Antibody–drug conjugates outperform chemotherapy in EGFR-TKI-resistant NSCLC, according to this Bayesian network meta-analysis. What does this mean for post-TKI treatment strategies? 🔗 Read now: buff.ly/mBdISSD #Oncology #NSCLC #LungCancer #ADCs #CancerResearch

🧬 New review: What are the current standards, and what’s next, for platinum-refractory male germ cell cancers? This article explores evolving strategies and future directions in a challenging treatment landscape. 🔗 Read more: buff.ly/QqtRKue #Oncology #GermCellTumors #CancerResearch #Urology

📊 New real-world evidence:How do apalutamide and enzalutamide compare for PSA response in metastatic castration-sensitive prostate cancer? This study provides important comparative insights to inform treatment decisions. 🔗 Read now: buff.ly/CsFU3XV #ProstateCancer #Oncology #RealWorldEvidence #mCSPC

🧪 New study protocol published! TROPION-Lung14 (phase III) evaluates osimertinib + datopotamab deruxtecan vs osimertinib alone in 1L EGFR-mutated advanced NSCLC. Could combination therapy reshape first-line treatment? 🔗 Read more: buff.ly/pp3eAk2 #Oncology #LungCancer #NSCLC #ClinicalTrials #EGFR

📣 Call for Papers: Advances in Targeted Therapeutics for Pancreatic Cancer: Redefining Precision Oncology in the KRAS Era ✅ Open now | 📅 Deadline Mar 1, 2027 KRAS targeting, resistance, combinations, beyond KRAS & advanced models. 🔗 buff.ly/eMwzb2N #PancreaticCancer #KRAS #Oncology #CallForPapers

🆕 New - Does timing matter in radiotherapy? This study shows that time‑of‑day radiotherapy influences radiation pneumonitis risk, but not survival, in #lungcancer patients with #ILD 🔗 buff.ly/vvUviVC #Radiotherapy #CancerToxicity #Oncology

🧠📣 New Special Collection in Ther Adv Med Oncol: #ADCs in Gynecologic Cancers. We invite clinically focused work on ADC targets, sequencing, toxicity, and combinations in ovarian, endometrial, and cervical cancers. 🗓️ Deadline: 26 Feb 2027 buff.ly/30K8r13 #GyneOnc #CancerTrials

Using spatial profiling, scRNA‑seq, and transcriptomic meta‑analysis, this study links S100A4⁺ antigen‑presenting CAFs with immune‑rich niches and complete resection outcomes in relapsed ovarian cancer. buff.ly/hL0LhWe #OvarianCancer #TumorMicroenvironment #CAFs

Precision approaches have reshaped AML care, yet relapse and resistance remain major challenges. This Collection seeks clinically grounded and translational work addressing MRD, molecular risk, immune strategies, and treatment sequencing across #AML. Deadline: 19 Feb 2027 buff.ly/xsqkygl

In resected #AcralMelanoma, this multicenter retrospective study found adjuvant anti‑PD‑1 therapy achieved RFS comparable to high‑dose interferon, with substantially fewer grade 3–4 toxicities. KIT‑mutant disease showed a signal of greater benefit. Ther Adv Med Oncol buff.ly/QukRAI9 #Immunotherapy

After the strong response to Volume 1, this second volume of our #ADC Special Collection reflects how rapidly these agents are redefining breast cancer treatment-from sequencing questions to biomarkers and toxicity management. Submissions open until 29 Jan 2027 buff.ly/RS4HyAZ #BreastCancerResearch

Later-line #pancreaticcancer care lacks validated prognostic tools. The NAPOLEON‑2 study explores how prior treatment duration, line of therapy, and inflammation (CAR) relate to PFS with nanoliposomal irinotecan + 5‑FU/LV - proposing a clinically grounded nomogram. buff.ly/0XFh0X5 #MedicalOncology

Immunotherapy for #TCellMalignancies raises unique challenges-from antigen overlap to CAR‑T fratricide. This Special Collection brings together translational and early clinical insights addressing these barriers. Submissions open until 29 Jan 2027 Ther Adv Med Oncol buff.ly/y2kbSVy

Can intensified strategies improve outcomes in advanced #biliarycancer? This multicentre #realworld study reports outcomes of a highly selected subset treated with chemo‑immunotherapy followed by multimodality local approaches in the #immunotherapy era. buff.ly/Ygnhnjn Ther Adv Med Oncol #Oncology

Biomarkers are now shaping #LungCancer care across the entire disease continuum. This Collection in Ther Adv Med Oncol examines how biomarker‑driven strategies are being translated into clinical practice. Submit by January 29, 2027 buff.ly/RrkerAu

Real‑world data can complement trial evidence. In this retrospective Chinese cohort, sacituzumab govitecan showed activity in metastatic #BreastCancer, with exploratory analyses suggesting potential associations with prior immunotherapy and PIK3CA status. buff.ly/6v5lzLX #TranslationalResearch #ADC

The therapeutic landscape of HR+HER2‑ advanced #BreastCancer has expanded rapidly, yet heterogeneity, resistance, and treatment sequencing remain unresolved challenges. This Collection in Ther Adv Med Oncol focuses on research shaping a more individualized therapeutic roadmap. buff.ly/Da8ENXI